^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TERT promoter mutation

i
Other names: TERT, Telomerase Reverse Transcriptase, Telomerase-Associated Protein 2, Telomerase Catalytic Subunit, HEST2, EST2, TCS1, TP2, TRT, PFBMFT1, DKCA2, DKCB4, CMM9, HTR
Entrez ID:
Related biomarkers:
11ms
New trial
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • TERT (Telomerase Reverse Transcriptase) • BAP1 (BRCA1 Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NF2 (Neurofibromin 2) • KLF4 (Kruppel-like factor 4)
|
CDKN2A deletion • NF2 mutation • TERT mutation • TERT promoter mutation
11ms
Clinicopathologic and genomic characteristics of biliary tract carcinomas with TERT promoter mutations among East Asian population. (PubMed, Pathol Res Pract)
In conclusion, TERT mutations in biliary tract carcinomas had unique clinicopathologic and genetic characteristics. Despite its poor PFS, the concomitant presence of ERBB2 amplification and a high TMB indicated a potential for targeted therapy and immunotherapy in this specific subtype.
Journal • Tumor mutational burden • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • TERT (Telomerase Reverse Transcriptase) • PBRM1 (Polybromo 1) • SMAD4 (SMAD family member 4)
|
TP53 mutation • KRAS mutation • TMB-H • HER-2 amplification • HER-2 mutation • PBRM1 mutation • TERT mutation • TERT promoter mutation
11ms
Potentially actionable molecular alterations in particular related to poor oncologic outcomes in salivary gland carcinomas. (PubMed, BMC Cancer)
SGCs are a heterogeneous group of malignancies with distinct molecular landscape that characterized by poor prognosis and inadequate treatment options. Nonstandard strategies might be beneficial for patients who suffer from salivary gland cancers. Wider utilization of NGS analysis may increase the opportunity for patients with those rare cancers to receive more precise, personalized therapy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
TP53 mutation • CDKN2A deletion • TERT mutation • TERT promoter mutation
11ms
Ovarian Adult Granulosa Cell Tumors: A Scoping Review of DNA Alterations and Their Known Significance. (PubMed, Anticancer Res)
The FOXL2 missense mutation was the only common somatic DNA alteration in aGCT. TERT promoter mutations were reported more frequently in recurrent aGCT but their clinical relevance remains uncertain. In contrast to previous reports, truncating KMT2D mutations were not found to be associated with recurrent aGCT. Evidence on common germline variants in aGCT is sparse. The role of somatic and germline DNA alterations in the development of other malignancies in women with aGCT remains uncertain. Further research involving matched primary and recurrent tumors, as well as other primary malignancies, is essential to better understand the mutations that drive tumor development.
Review • Journal • Tumor mutational burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • TERT (Telomerase Reverse Transcriptase) • KMT2D (Lysine Methyltransferase 2D) • FOXL2 (Forkhead Box L2)
|
TP53 mutation • TMB-L • KMT2D mutation • TERT mutation • TERT promoter mutation
11ms
Assessment of MGMT and TERT Subtypes and Prognosis of Glioblastoma by Whole Tumor Apparent Diffusion Coefficient Histogram Analysis. (PubMed, Brain Behav)
ADC histogram analysis may be a potential noninvasive biomarker for differentiating MGMT and TERT molecular markers and providing prognostic information for GBM patients.
Retrospective data • Journal
|
MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
|
MGMT promoter methylation • TERT mutation • TERT promoter mutation
11ms
High p16INK4A expression in glioblastoma is associated with senescence phenotype and better prognosis. (PubMed, Neoplasia)
The released CCL13 enhances the infiltration of T cells within the tumor, potentially contributing to the improved prognosis observed in patients with high p16INK4A expression. These findings suggest that tumor cells with a senescence phenotype in GBM, through the secretion of chemokines such as CCL13, may augment immune cell infiltration and potentially enhance patient outcomes by creating a more immunologically active tumor microenvironment.
Journal
|
EGFR (Epidermal growth factor receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
EGFR mutation • EGFR amplification • CDKN2A deletion • TERT mutation • TERT promoter mutation • CDKN2A expression
12ms
BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression. (PubMed, Front Endocrinol (Lausanne))
BRAFmutpTERTwt had higher stromal lymphocytes infiltration as compared to BRAFwtpTERTwt tumors, corroborating the transcriptomic findings. To our knowledge this is the first report of a potential link between TERT and the immune microenvironment, offering an explanation for the aggressive nature of BRAFmutpTERTmut PTC.
Journal
|
BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
|
BRAF V600E • BRAF V600 • TERT mutation • TERT promoter mutation
|
nCounter® PanCancer Immune Profiling Panel
12ms
Molecular profile of adult primary leptomeningeal gliomatosis aligns with glioblastoma, IDH-wildtype. (PubMed, Brain Pathol)
Only one case, with relatively localized disease at diagnosis, received chemoradiation therapy and survived 535 days, raising the possibility that early diagnosis and timely treatment could improve outcome. A detailed list of previously reported cases is provided in a supplementary table.
Journal
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • GLI1 (GLI Family Zinc Finger 1)
|
TP53 mutation • PTEN mutation • CDKN2A deletion • CDK4 amplification • TERT mutation • TERT promoter mutation
12ms
Predicting recurrence in adult granulosa cell tumors: the role of Ki67, p53, and TERT mutations. (PubMed, Arch Gynecol Obstet)
Identifying patients with high Ki67 and mutational p53 together with TERT mutations may help predict potential recurrence in aGCT cases.
Journal
|
TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
|
TP53 mutation • TERT mutation • TERT promoter mutation • CD73 expression
12ms
Radiological, clinical, and molecular analyses reveal distinct subtypes of butterfly glioblastomas affecting the prognosis. (PubMed, Neurooncol Adv)
Our results highlight that the radiological features of bGB are not homogenous and can indicate 2 potential subtypes based on their origins. Further studies are mandatory, but CC-type and Hemispheric-type exhibit distinct clinical backgrounds, outcomes, and molecular features.
Journal
|
BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase) • H3-3A (H3.3 Histone A)
|
BRAF mutation • TERT mutation • TERT promoter mutation
12ms
High Prevalence of TBC1D12 5'UTR Mutations in Anaplastic Thyroid Cancer. (PubMed, Thyroid)
TBC1D12 5'UTR mutations were significantly associated with older age at diagnosis (60 vs. 46 for wild type, p = 0.003), pathological T3/T4 stage (85.7% vs. 37.7%, p = 0.010), and advanced tumor stages (85.7% vs. 32.5%, p = 0.006) in PTC. This preliminary study for the first time showed a high prevalence of TBC1D12 5'UTR mutations in ATC and indicated an association between TBC1D12 mutation and aggressive characteristics of PTC, which needs to be confirmed in large cohort studies.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • TERT (Telomerase Reverse Transcriptase) • ADGRG6 (Adhesion G Protein-Coupled Receptor G6) • SDHD (Succinate Dehydrogenase Complex Subunit D)
|
BRAF V600E • TMB-H • BRAF V600 • TERT mutation • TERT promoter mutation